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Resection of T4 hepatocellular carcinomas with adjacent structures, is it justified? 
Running title: Resect T4 HCCs with adjacent structures 
 
Abstract 
Background: T4 hepatocellular carcinoma (HCC) with invasion to adjacent structure(s) 
may require resection of not only the tumor but also the invaded structure(s). 
Method: Adult patients with T4 HCC were divided into groups. Patients whose tumors 
and invaded adjacent structures were resected together in combined resection were 
assigned to Group 1 if they had histopathologically confirmed tumor invasion or Group 2 if 
they had histopathologically confirmed tumor adhesion. Group 3 consisted of patients who 
received tumor resection only. Group comparisons were made. 
Results: Totally 144 patients were included in the study. There were 71, 14 and 59 
patients in Group 1, 2 and 3 respectively. The groups were comparable in demographics, 
complication and survival. Ten hospital deaths occurred (5, 0 and 5 in Group 1, 2 and 3 
respectively; p=0.533.) The 5-year overall survival (hospital mortality excluded) was 17.8% in 
Group 1, 14.3% in Group 2, and 28.9% in Group 3 (p=0.191). The 5-year disease-free survival 
was 10.4% in Group 1 and 14.5% in Group 3 (no data for Group 2 yet) (p=0.565). On 
multivariate analysis, combined resection was not a risk factor for survival whereas 
macrovascular invasion and poor differentiation were. 
Conclusions: Combined resection achieved survival outcomes similar to mere tumor 
resection, with an acceptably but not significantly higher risk. Patients with tumor invasion 
and patients with tumor adhesion had comparable survival after combined resection. At 
centers with the required expertise, combined resection should be attempted to treat T4 
HCCs with clinically suspected invasion of adjacent structures. 
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Introduction 
The outcomes of hepatic resection for hepatocellular carcinoma (HCC) have improved 
significantly in recent years because of better surgical techniques and perioperative care1. 
HCC is a common malignancy in many Asian countries where hepatitis B virus infection is 
prevalent. It is the fourth most common cancer and the third cause of cancer-related deaths 
in Hong Kong2. A rising trend in HCC has also been observed recently in developed countries 
such as the United States and the United Kingdom3. Locally advanced T4 HCC carries a poor 
prognosis if left untreated, and only 10-37% of the patients are suitable for surgery because 
of the advanced stage at presentation and limited hepatic functional reserve from 
underlying chronic liver disease1, 4-5. 
Complete surgical resection of T4 HCCs provides the best chance of a cure6. HCCs with 
direct invasion of adjacent organs or structures require resection of not only the tumors but 
also the invaded organs or structures, but there are few reports documenting the safety 
profile and outcomes of such combined resection7-11. Most of the time, the ‘invasion’ is 
actually a dense desmoplastic reaction which cannot be differentiated on the operative field. 
This study assessed whether such combined resection for T4 HCC is justifiable. It also 
compared combined resection for tumor invasion, combined resection for tumor adhesion 
and mere tumor resection (for tumors not adhering to any surrounding structure) in terms 
of survival outcomes. 
 
Patients and Methods 
This retrospective study reviewed the prospectively collected data of the 1387 patients 
who underwent liver resection for HCC at our hospital during the period from December 
1989 to December 2010. The study period was divided into Era 1 (1989-1999) and Era 2 
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(2000-2010) in order to reflect the effect of technical advancement on the survival outcomes. 
Patients with extrahepatic disease were excluded. A total of 144 adult patients with T4 HCC 
were divided into 3 groups. Patients whose tumors and invaded adjacent organs or 
structures were resected together in combined resection were assigned to Group 1 if they 
had histopathologically confirmed tumor invasion or Group 2 if they had histopathologically 
confirmed tumor adhesion. Group 3 consisted of patients who received only resection of 
tumors as the tumors breached the visceral peritoneum only and did not adhere to any 
surrounding organ or structure. 
 
Diagnosis and Preoperative Assessment 
Diagnosis of HCC was based on typical imaging findings (i.e. early arterial enhancement 
with early portovenous washout) on computed tomography (CT) or magnetic resonance 
imaging and/or a serum α-fetoprotein level of >400 ng/mL. Percutaneous needle biopsy was 
not routinely performed on patients with resectable tumors to avoid needle-tract seeding of 
tumor cells. 
A patient was eligible for resection if he or she had adequate hepatic functional reserve 
and no extrahepatic disease, and if the tumor was anatomically resectable as evaluated by 
imaging studies. Hepatic function assessment in terms of Child-Pugh classification12 and 
indocyanine green clearance test was performed routinely. During the period from 1989 to 
1993, the decision for laparotomy was based mainly on Child-Pugh classification. Child-Pugh 
class C was regarded as a contraindication to hepatectomy. After the indocyanine green 
clearance safety limit for major hepatectomy was determined in 199513, patients’ suitability 
for surgery was based largely on their results of indocyanine green clearance tests rather 
than their Child-Pugh classes. Patients with an indocyanine green retention rate ≤14% at 15 
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minutes were eligible for major hepatectomy14. Since 2010, dual-tracer positron emission 
tomography was performed when extrahepatic metastasis was suspected. 
 
Surgical Management 
Our techniques of hepatic resection have been standardized over the years1. Briefly, the 
operation started with a bilateral subcostal incision or a right subcostal incision with an 
upward midline extension. Assessment of resectability by intraoperative ultrasonography 
was routinely done to detect any major vascular invasion in the contralateral lobe and 
undetected tumor in the future liver remnant and to mark the plane of transection. The 
anterior approach was adopted for patients with large tumors to minimize tumor 
manipulation before division of all vascular attachments. Parenchymal transection was 
performed using the finger-fracture technique from 1989 to 1992, and thereafter using an 
ultrasonic dissector. Central venous pressure was kept below 5 mmHg as far as possible. 
Hemostasis during hepatic transection was achieved by diathermy coagulation, argon beam 
coagulation or fine suturing. Intermittent hepatic inflow occlusion was applied during 
hepatic transection only if excessive bleeding was encountered. Routine bile leakage test 
was performed by methylene blue injection via a cannula placed inside the common bile 
duct through the cystic duct after transection. If tumor involvement with an adjacent organ 
or structure was suspected, the organ or structure was resected together. Since 2002, 
intra-abdominal drain was not used15. Since 2009, patients with chronic active hepatitis B 
were given antivirals. No medical therapy was given to patients with chronic hepatitis C. 
 
Postoperative Management 
All patients were admitted to the intensive care unit or the high dependency unit 
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during the early postoperative period and received broad-spectrum antibiotics for 5 days. 
For patients with cirrhosis, parenteral nutrition in the form of branched-chain 
amino-acid-enriched solution, low-dose dextrose and medium- and long-chain triglycerides 
was provided via a surgically placed central line until oral feeding could be well tolerated. 
All patients were followed up monthly in the first year and quarterly afterwards, with 
regular monitoring for recurrence by serum α-fetoprotein level check and CT of the liver. CT 
of the liver was done one month after hepatectomy and then every two to four months. 
Diagnosis of recurrence was based on typical imaging findings; percutaneous find-needle 
aspiration cytology was also performed if necessary. Since 2010, dual-tracer positron 
emission tomography was performed when indefinite recurrences were encountered16. A 
standardized aggressive management protocol as described in a previous report was 
adopted to treat recurrences17. 
 
Definitions 
The American Joint Committee on Cancer tumor-node-metastasis system for staging of 
primary liver cancer (7th edition) was used. An HCC was defined as T4 if there was direct 
invasion of adjacent organs other than the gallbladder, or perforation of the visceral 
peritoneum. A hepatic resection was classified as a major resection if three or more 
segments (according to the Couinaud classification) were resected18. If fewer than three 
segments were resected, it was a minor resection. Hospital mortality was defined as death 
occurring during the hospital stay for primary operation. Complication was defined as any 
deviation from the normal postoperative course with the need for pharmacological, surgical, 
endoscopic or radiological intervention. All complications were prospectively documented 
and graded according to the Clavien-Dino classification19. 
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Statistical Analysis 
Pearson’s chi-squared test or Fisher’s exact test was used where appropriate to 
compare categorical variables. Patients were matched according to T4 tumor status, tumor 
size, tumor number and age, and were divided into three groups. The Kruskal-Wallis test was 
used to compare the continuous variables of the three groups of patients. Univariate 
analyses of possible risk factors associated with overall survival and disease-free survival 
respectively were performed with a logistic regression model, and factors with p≤0.1 were 
put into the Cox regression hazard model to determine independent risk factors associated 
with overall survival and disease-free survival respectively. The Kaplan-Meier method was 
used for survival analyses, and the log-rank test was used to compare variables. P<0.05 
denoted statistical significance and all p values were two-tailed. 
 
Results 
One hundred and forty-four patients were included in the study. There were 71, 14 and 
59 patients in Group 1, 2 and 3 respectively. It turned out that about 16.5% (14/85) of the 
patients who received combined resection had tumor adhesion rather than tumor invasion. 
As shown in Table 1, the three groups had comparable demographic data and 
preoperative clinical characteristics. Table 2 shows the operative data and tumor 
characteristics and Table 3 shows the postoperative data, complication details and 
recurrence patterns in the three groups. They were all comparable. The most commonly 
resected organ or structure was the diaphragm (56 in Group 1 and 11 in Group 2), followed 
by the colon (8 in Group 1 and 1 in Group 2) and the stomach (3 in Group 1 and 3 in Group 
2). Six out of the 71 patients in Group 1 had tumor rupture causing invasion of the 
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diaphragm. 
In the search for risk factors for overall survival, presence of macrovascular invasion, 
higher serum α-fetoprotein level, longer prothrombin time, bigger operative blood loss 
amount, poorer tumor grading, and presence of postoperative complication were identified 
in univariate analysis, whereas presence of macrovascular invasion, poorer tumor grading, 
and presence of postoperative complication were identified in multivariate analysis. In the 
search for risk factors for disease-free survival, higher serum α-fetoprotein level, higher 
serum total bilirubin level, higher serum aspartate transaminase level, bigger operative 
blood loss amount, bigger tumor size, and poorer tumor grading were identified in 
univariate analysis, whereas higher serum total bilirubin level, bigger tumor size, and poorer 
tumor grading were identified in multivariate analysis. 
Both Groups 1 and 3 had five hospital deaths, whereas no death occurred in Group 2 
(Table 3). Figure 1 compares the three groups of patients in terms of overall survival and 
disease-free survival with hospital deaths excluded. No survival differences were found. 
Subgroup analyses in terms of overall survival and disease-free survival were conducted to 
compare patients who had their diaphragms resected with patients who had other organs or 
structures resected. Again, no differences were found. 
 
Discussion 
There is a spectrum of locally advanced HCCs, ranging from those breaching only the 
visceral peritoneum to those invading other organs or structures. Those with invasion of 
surrounding organs or structures carry a poor prognosis. A previous study by our center 
found that patients with such disease had a median post-resection survival duration of 15.1 
months only20, which is similar to what was found in the present study – a median of around 
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17 months – despite advances in surgical treatment over the years. Patients with such 
disease also have a high incidence of recurrence because there is no effective adjuvant 
treatment for them. A randomized controlled trial in China reported a significantly higher 
disease-free survival rate in patients with postoperative transarterial chemoembolization 
and portal vein chemotherapy21. However, such postoperative treatment is not widely 
practiced; more randomized controlled trials are needed to validate the usefulness of 
adjuvant therapy for locally advanced HCCs. 
Tumor extension to an adjacent organ or structure does not necessarily indicate tumor 
invasion. According to various reports, only 7-43% of such extensions found during operation 
had final histological proof of direct invasion7,8,22,23. In the present study, it was 16.5%. Any 
attempt to separate a tumor from an adjacent organ or structure should be prohibited since 
it might cause torrential bleeding and tumor seeding. Although combined resection is 
technically challenging, it would not cause more blood loss or more major complications. 
In this study, the most commonly resected organ or structure was the diaphragm. Six 
patients had tumor rupture that caused direct invasion of the diaphragm. The study echoes 
the report by Lau et al.24 that diaphragm removal could result in curative resection and did 
not cause more significant morbidities. 
There were more bilobar tumors in Group 2, which had the worst overall survival and 
disease-free survival, but univariate analysis did not demonstrate a significant impact of 
bilobar disease on overall survival. However, there were only 14 patients in this group, 
making it impossible to conduct a meaningful further analysis or draw any conclusion. 
Multivariate analysis showed that combined resection and era were not risk factors for 
overall or disease-free survival. Macrovascular invasion, poor tumor cell differentiation and 
postoperative complication were found to be risk factors for overall survival. Among these 
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risk factors, the last one is the only one that can be attenuated or removed by a surgeon 
with good surgical skills. Previous study from our center already demonstrated that the 
presence of postoperative complication could affect survival outcomes25. As combined 
resection itself does not cause more hospital deaths or postoperative morbidities but 
provides the only chance of a cure, it should be attempted as far as possible. 
This study is a single-center one and has a retrospective nature, which means selection 
bias is inevitable. It also covers a long period, which has made data intrepretation difficult 
since different surgical techniques and management protocols were employed over the 
years. However, imaging modalities were more or less the same over the years, and surgical 
exploration was carried out in case of doubt. If invasion was suspected, combined resection 
was performed whenever possible. Although there has been advancement in 
multidisciplinary input in the management of T4 HCC, resection is still by far the most 
promising treatment provided that it can remove the tumor bulk and eradicate associated 
symptoms (gastrointestinal bleeding in case of colon invasion if left untouched).  
Ideally, patients with T4 HCCs without surgery should have been studied too, but these 
patients were under the care of oncologists rather than surgeons, and had these patients 
been included, the patient profile would have been totally different (e.g. there would be 
significant comorbidities making surgery unsafe). Hence, they were not included in the 
present study. However, the study has by far the largest series reported. Hopefully it can 
shed light on the management of patients with such difficult disease. Before a more 
appealing treatment is available, combined resection should be the treatment of choice for 
these patients at centers with the required expertise. 
In conclusion, combined resection achieved survival outcomes similar to mere tumor 
resection, with an acceptably but not significantly higher risk. Patients with tumor invasion 
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and patients with tumor adhesion had comparable survival after combined resection. At 
centers with the required expertise, combined resection should be attempted to treat T4 
HCCs with clinically suspected invasion of adjacent organs or structures. 
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Table 1. Demographic data and preoperative clinical characteristics in the three groups 
 Group 1 (n=71) Group 2 (n=14) Group 3 (n=59) P 
Age (years) 55 (35-80) 57 (39-76) 52 (30-79) 0.884 
Sex (male : female) 9 (12.7%) 3 (21.4%) 8 (13.6%) 0.685 
HBV infection 
Not known 
Negative 
Positive 
 
1 (1.4%) 
15 (21.1%) 
55 (77.5%) 
 
0 (0%) 
0 (0%) 
14 (100%) 
 
2 (3.4%) 
9 (15.3%) 
48 (81.4%) 
0.296 
 
 
 
HCV infection 
Not known 
Negative 
Positive 
 
26 (36.6%) 
43 (60.6%) 
2 (2.8%) 
 
2(14.3%) 
12 (85.7%) 
0 (0%) 
 
22 (37.3%) 
33 (55.9%) 
4 (6.8%) 
0.251 
 
 
 
Comorbidity 19 (26.8%) 3 (21.4%) 16 (27.1%) 0.905 
Cardiovascular 
Pulmonary 
Renal 
Diabetes mellitus 
Gastrointestinal 
12 (16.9%) 
4 (5.6%) 
2 (2.8%) 
7 (9.9%) 
5 (7%) 
2 (14.3%) 
1 (7.1%) 
0 (0%) 
1 (7.1%) 
1 (7.1%) 
9 (15.3%) 
5 (8.5%) 
2 (3.4%) 
3 (5.1%) 
4 (6.8%) 
0.952 
0.817 
0.786 
0.593 
0.998 
AFP (ng/mL) 926 (2-1335900) 4681 (5-236790) 250.5 (2-481000) 0.323 
Creatinine (umol/L) 85.5 (52-152) 85 (66 -110) 87 (57-1710 0.580 
Platelet (×109/L) 207 (66-554) 211 (137-813) 209 (78-621) 0.809 
Total bilirubin (umol/L) 13 (5-38) 11 (6-19) 13 (4-42) 0.465 
Albumin (g/L) 39 (29-49) 38 (26-46) 39 (26-46) 0.492 
AST (U/L) 66.5 (22-248) 72.5 (42-1324) 54 (17-268) 0.224 
ALT (U/L) 47.5 (9-376) 53.5(25-248) 43(7-144) 0.370 
INR 1 (0.8-1.4) 1 (0.9-1.2) 1.1 (0.9-1.4) 0.594 
ICG15 10.9 (2-32.1) 9.85 (1.7-19.4) 9.7 (2.4-39.2) 0.522 
Child-Pugh class 
A 
B 
 
70 (98.6%) 
1 (1.4%) 
 
14 (100%) 
0 (0%) 
 
52 (88.1%) 
7 (11.9%) 
0.022 
 
 
 
Data are presented in median with range or number with percentage. 
HBV = hepatitis B virus 
HCV = hepatitis C virus 
AFP = α-fetoprotein 
AST = aspartate transaminase 
ALT = alanine transaminase 
INR = international normalized ratio 
ICG15 = indocyanine green retention rate at 15 minutes 
HBPDINT-16-0064.R2 
 
15 
 
Table 2. Operative data and tumor characteristics in the three groups 
 Group 1 (n=71) Group 2 (n=14) Group 3 (n=59) P 
Blood loss (L) 1.6 (0.1-8.0) 1.6 (0.7-7.13) 1.6 (0.1-8.9) 0.483 
Blood replacement (L) 0 (0-3.5) 0 (0-2.36) 0.6 (0-6.27) 0.227 
Lymph node metastasis 1 (1.4%) 0 (0%) 0 (0%) 0.596 
Microvascular permeation 55 (77.5%) 10 (71.4%) 34 (57.6%) 0.051 
Macrovascular invasion 12 (16.9%) 1 (7.1%) 7 (11.9%) 0.529 
Size of tumor (cm) 11 (3.5-27) 11.5 (5-16) 10 (2-22) 0.073 
No. of tumor nodule 1 (1-multiple) 1 (1-multiple) 1 (1-multiple) 0.472 
No. of tumor nodule 
One 
More than one 
 
45 (63.4%) 
26 (36.6%) 
 
11 (78.6%) 
3 (21.4%) 
 
33 (55.9%) 
26 (44.1%) 
0.272 
 
 
Bilobar disease 6 (8.5%) 5 (35.7%) 12 (20.3%) 0.019 
Invasion of adjacent organ 
or structure other than the 
gallbladder 
71 (100%) 0 (0%) 0 (0%) <0.0001 
 
Data are presented in median with range or number with percentage. 
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Table 3. Postoperative data, complication details and recurrence patterns in the three groups 
 Group 1 (n=71) Group 2 (n=14) Group 3 (n=59) P 
Hospital stay (days) 14 (5-89) 16 (6-22) 11 (6-87) 0.362 
Hospital death 5 (7%) 0 (0%) 5 (8.5%) 0.533 
With complication 30 (42.3%) 7 (50%) 20 (33.9) 0.440 
Chest infection 
Chest infection requiring bronchoscopy 
Chest infection requiring tracheostomy 
Pleural effusion requiring drainage 
Wound infection 
Wound dehiscence 
Subphrenic abscess 
Intra-abdominal bleeding 
Urinary tract infection 
Cardiac arrhythmia 
Heart failure 
Biliary fistula or leakage 
Infected ascites 
Pneumothorax 
Liver failure 
Renal failure 
Subphrenic collection requiring drainage 
6 (8.5%) 
3 (4.2%) 
2 (2.8%) 
4 (5.6%) 
6 (8.5%) 
1 (1.4%) 
1 (1.4%) 
4 (5.6%) 
0 (0%) 
6 (8.5%) 
1 (1.4%) 
3 (4.2%) 
1 (1.4%) 
3 (4.2%) 
5 (7%) 
4 (5.6%) 
0 (0%) 
1 (7.1%) 
0 (0%) 
0 (0%) 
2 (14.3%) 
1 (7.1%) 
0 (0%) 
0 (0%) 
0(0%) 
0 (0%) 
1 (7.1%) 
0 (0%) 
0 (0%) 
0 (0%) 
1 (7.1%) 
0 (0%) 
0 (0%) 
0 (0%) 
4 (6.8%) 
2 (3.4%) 
1 (1.7%) 
6 (10.2%) 
2 (3.4%) 
1 (1.7%) 
2 (3.4%) 
2 (3.4%) 
1 (1.7%) 
1 (1.7%) 
0 (0%) 
1 (1.7%) 
0 (0%) 
0 (0%) 
4 (6.8%) 
3 (5.1%) 
1 (1.7%) 
0.936 
0.732 
0.768 
0.378 
0.489 
0.888 
0.622 
0.583 
0.484 
0.237 
0.596 
0.547 
0.596 
0.199 
0.595 
0.666 
0.484 
With complication of Clavien 3a or above 20 (28.2%) 6 (42.9%) 16 (27.1%) 0.491 
Clavien 3a 
Clavien 3b 
Clavien 4a 
Clavien 4b 
Clavien 5 
14 (19.7%) 
1 (1.4%) 
0 (0%) 
- 
5 (7%) 
6 (42.9%) 
0 (0%) 
0 (0%) 
- 
0 (0%) 
9 (15.3%) 
2 (3.4%) 
5 (2.2%) 
- 
5 (8.5%) 
0.068 
0.622 
0.317 
- 
0.533 
Pattern of recurrence 
No recurrence 
Intrahepatic recurrence 
Extrahepatic recurrence 
Both 
 
17 (23.9%) 
15 (21.1%) 
18 (25.4%) 
21 (29.6%) 
 
1 (7.1%) 
3 (21.4%) 
4 (28.6%) 
6 (42.9%) 
 
14 (23.7%) 
18 (30.5%) 
9 (15.3%) 
18 (30.5%) 
0.498 
 
 
 
 
Median follow-up period (months) 12.9 (0.26-184.88) 
19.06 
(5.03-96.81) 
25.3 
(0.26-199.7) 0.437 
 
Data are presented in median with range or number with percentage. 
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Figure 1. Survival Comparison 
 
